Table 3.
Description of neutropenia events
| Category, n (%) | P + AI (N = 85) | P + Ful (N = 54) | Overall (N = 139) |
|---|---|---|---|
| Number of events, number and (%) of patients with neutropenia onset by cycle | |||
| Cycle 1 | 41, 30 (35%) | 24, 22 (41%) | 65, 52 (37%) |
| Cycle 2 | 15, 13 (15%) | 14, 12 (22%) | 29, 25 (18%) |
| Cycle 3 | 9, 8 (9%) | 10, 8 (15%) | 19, 16 (12%) |
| Cycle 4 | 10, 7 (8%) | 4, 4 (7%) | 14, 11 (8%) |
| Cycle 5 | 13, 7 (8%) | 2, 2 (4%) | 15, 9 (6%) |
| Cycle 6 | 1, 1 (1%) | 2, 2 (4%) | 3, 3 (2%) |
| Severity of neutropenia (number of events, number and (%) of patients)a | |||
| Grade 1 | 27, 17 (20%) | 16, 7 (13%) | 43, 24 (17%) |
| Grade 2 | 34, 22 (26%) | 21, 15 (28%) | 55, 37 (27%) |
| Grade 3 | 29, 18 (21%) | 21, 16 (30%) | 50, 34 (24%) |
| Grade 4 | 3, 3 (4%) | 0, 0 (0%) | 3, 3 (2%) |
| Number of events, number and (%) of patients with dose adjustment or treatment interruption due to neutropenia | 26, 18 (21%) | 19, 14 (26%) | 45, 32 (23%) |
| Dose adjustment | 7, 6 (7%) | 9, 9 (17%) | 16, 15 (11%) |
| Treatment interruption | 19, 13 (15%) | 10, 9 (17%) | 29, 22 (16%) |
aAs graded by investigators per CTCAE